We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Boston Scientific Corporation (BSX) is a leading medical devices business with stocks listed in the US. It opened the day at US$42.31 after a previous close of US$42.31. During the day the price has varied from a low of USD42.03 to a high of USD42.8. The latest price was USD42.57 (25 minute delay). Boston Scientific Corporation is listed on the NYSE. All prices are listed in US Dollars.
How to buy shares in Boston Scientific Corporation
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Boston Scientific Corporation. Find the share by name or ticker symbol: BSX. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Boston Scientific Corporation reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Boston Scientific Corporation, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Boston Scientific Corporation. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
- Boston Scientific Corporation key stats
- Compare share trading platforms
- Is Boston Scientific Corporation stock a buy or sell?
- Boston Scientific Corporation performance over time
- Can I short Boston Scientific Corporation shares?
- Is Boston Scientific Corporation suitable for ethical investing?
- Are Boston Scientific Corporation shares over-valued?
- Boston Scientific Corporation's financials
- How volatile are Boston Scientific Corporation shares?
- Does Boston Scientific Corporation pay a dividend?
- Have Boston Scientific Corporation shares ever split?
- Other common questions
Boston Scientific Corporation share priceUse our graph to track the performance of BSX stocks over time.
Boston Scientific Corporation shares at a glance
|52-week range||US$32.99 - US$42.54|
|50-day moving average||US$39.0146|
|200-day moving average||US$37.1631|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||US$2.605|
Compare share trading platforms to buy stock
Is it a good time to buy Boston Scientific Corporation stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Boston Scientific Corporation price performance over time
|1 week (2021-04-15)||4.19%|
|1 month (2021-03-19)||11.53%|
|3 months (2021-01-22)||14.96%|
|6 months (2020-10-23)||14.53%|
|1 year (2020-04-23)||16.95%|
|2 years (2019-04-23)||18.61%|
|3 years (2018-04-23)||47.71%|
|5 years (2016-04-22)||115.44%|
Is Boston Scientific Corporation under- or over-valued?
Valuing Boston Scientific Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Boston Scientific Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Boston Scientific Corporation's P/E ratio
Boston Scientific Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 15x. In other words, Boston Scientific Corporation shares trade at around 15x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Boston Scientific Corporation's PEG ratio
Boston Scientific Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.1133. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Boston Scientific Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Boston Scientific Corporation's EBITDA
Boston Scientific Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$2.3 billion (£1.6 billion).
The EBITDA is a measure of a Boston Scientific Corporation's overall financial performance and is widely used to measure a its profitability.
Boston Scientific Corporation financials
|Revenue TTM||US$9.9 billion|
|Operating margin TTM||11.39%|
|Gross profit TTM||US$6.8 billion|
|Return on assets TTM||2.3%|
|Return on equity TTM||-0.56%|
|Market capitalisation||US$60.1 billion|
TTM: trailing 12 months
Shorting Boston Scientific Corporation shares
There are currently 15.1 million Boston Scientific Corporation shares held short by investors – that's known as Boston Scientific Corporation's "short interest". This figure is 15.3% down from 17.8 million last month.
There are a few different ways that this level of interest in shorting Boston Scientific Corporation shares can be evaluated.
Boston Scientific Corporation's "short interest ratio" (SIR)
Boston Scientific Corporation's "short interest ratio" (SIR) is the quantity of Boston Scientific Corporation shares currently shorted divided by the average quantity of Boston Scientific Corporation shares traded daily (recently around 7.6 million). Boston Scientific Corporation's SIR currently stands at 1.98. In other words for every 100,000 Boston Scientific Corporation shares traded daily on the market, roughly 1980 shares are currently held short.
However Boston Scientific Corporation's short interest can also be evaluated against the total number of Boston Scientific Corporation shares, or, against the total number of tradable Boston Scientific Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Boston Scientific Corporation's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Boston Scientific Corporation shares in existence, roughly 10 shares are currently held short) or 0.0107% of the tradable shares (for every 100,000 tradable Boston Scientific Corporation shares, roughly 11 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Boston Scientific Corporation.
Find out more about how you can short Boston Scientific Corporation stock.
Boston Scientific Corporation's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Boston Scientific Corporation.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Boston Scientific Corporation's total ESG risk score
Total ESG risk: 29.23
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Boston Scientific Corporation's overall score of 29.23 (as at 12/31/2018) is nothing to write home about – landing it in it in the 57th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Boston Scientific Corporation is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Boston Scientific Corporation's environmental score
Environmental score: 1.51/100
Boston Scientific Corporation's social score
Social score: 12.87/100
Boston Scientific Corporation's governance score
Governance score: 7.87/100
Boston Scientific Corporation's controversy score
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Boston Scientific Corporation scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Boston Scientific Corporation hasn't always managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
|Total ESG score||29.23|
|Total ESG percentile||56.94|
|Level of controversy||3|
Boston Scientific Corporation share dividends
We're not expecting Boston Scientific Corporation to pay a dividend over the next 12 months.
Have Boston Scientific Corporation's shares ever split?
Boston Scientific Corporation's shares were split on a 2:1 basis on 5 November 2003. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Boston Scientific Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Boston Scientific Corporation shares which in turn could have impacted Boston Scientific Corporation's share price.
Boston Scientific Corporation share price volatility
Over the last 12 months, Boston Scientific Corporation's shares have ranged in value from as little as US$32.99 up to US$42.54. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Boston Scientific Corporation's is 0.8384. This would suggest that Boston Scientific Corporation's shares are less volatile than average (for this exchange).
Boston Scientific Corporation overview
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Frequently asked questions
Ask an Expert